不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD20xCD3 双特异性抗体对不同 CD20 表达水平弥漫大 B 细胞淋巴瘤（DLBCL）细胞系的体外比较
英文原题：In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.
查看英文原题
In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管CD20xCD3双特异性抗体（BsAbs）在弥漫性大B细胞淋巴瘤（DLBCL）中已显示出变革性活性，但部分患者无应答，另一些患者则复发。为初步探索可能的局限性，我们比较了四种CD20xCD3生物类似BsAbs对四种CD20表达跨度达100倍的DLBCL细胞系的体外活性。所有四种生物类似BsAbs均显示出优于利妥昔单抗的体外活性，其中生物类似glofitamab始终是最强效的。此外，生物类似glofitamab和odronextamab在低水平CD20表达情况下仍保留显著活性。最后，一种DLBCL细胞系尽管诱导了显著的T细胞和NK细胞活化，却对全部四种CD20xCD3 BsAbs表现出内在耐药性。
展开英文摘要原文
Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B-cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ranging over a 100-fold. All four biosimilar BsAbs demonstrated superior in vitro activity to rituximab, with biosimilar glofitamab consistently being the most potent.
Moreover, biosimilar glofitamab and odronextamab retained significant activity in the presence of low-level CD20 expression.
Finally, one DLBCL cell line exhibited intrinsic resistance to all four CD20xCD3 BsAbs despite inducing marked T-cell and NK-cell activation.
论文信息
- 作者
- Bray JS、Thomas GR、Smith VM、Wright A、Jayne S、Dyer MJS、Walter HS
- 单位
- The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.United Kingdom
- 文献类型
- 对照研究
- 期刊
- British journal of haematology2025 May
- 原文标识
- PubMed 40032583 · DOI 10.1111/bjh.20033
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →